- Trial phase
- Approved
- Time to market
- Already approved and marketed since December 2007.
- Why 3/10
- KUVAN is an already-approved, marketed drug with no pending regulatory decision or pivotal readout. It contributes only about 2% of BioMarin's total revenue and is in decline due to generic competition. No hard, dated binary catalyst exists for this drug in the next 12 months, so the impact score is capped at 3-5 per the rubric, and the declining commercial trajectory justifies the lower end of that range.
KUVAN has no upcoming regulatory catalysts or pivotal readouts; it is a mature, declining product facing generic erosion. For BioMarin investors, the focus should remain on VOXZOGO's growth trajectory, the integration of the Amicus acquisition (GALAFOLD, POMBILITI+OPFOLDA), and the PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia. KUVAN itself is not a stock-moving catalyst.
Price Chart
Executive Summary
KUVAN (sapropterin dihydrochloride) is an FDA-approved oral therapy for phenylketonuria (PKU), a rare genetic disorder. BioMarin launched it in 2007 as the first specific drug for PKU. The drug is now in late lifecycle: generic competition entered in 2023, and KUVAN revenue has been steadily declining. In Q3 2026, KUVAN contributed just $23 million to BioMarin's $1.025 billion in total quarterly revenue (roughly 2% of sales), down 4% year over year. The drug faces multiple generic competitors and is no longer a meaningful growth driver for BioMarin, which has shifted focus to VOXZOGO, GALAFOLD, and other pipeline assets.
How It Works
KUVAN is a synthetic version of a naturally occurring body chemical called tetrahydrobiopterin (BH4). In some people with PKU, the enzyme that breaks down the amino acid phenylalanine is partially dysfunctional. KUVAN acts as a "chaperone" that helps this enzyme work better, lowering phenylalanine levels in the blood. It is taken orally as a tablet or powder dissolved in liquid, alongside a phenylalanine-restricted diet.
Trial Status
KUVAN was approved by the FDA in December 2007 for phenylketonuria (PKU) and has been commercially marketed since then. No active pivotal clinical trials are ongoing for KUVAN; it is a mature, approved product.
The Two-Sided Case
Upcoming Catalysts
- None for KUVAN specifically. For BioMarin overall: Q4 2026 earnings (early 2027), PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report